QQ客服 官方微博 反馈留言

	PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
	Wang, Yan; Liu, Zhao-Peng
刊名	MINI-REVIEWS IN MEDICINAL CHEMISTRY
	2019
卷号	19期号:2页码:165-176
关键词	Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9) low-density lipoprotein cholesterol (LDL-C) low-density lipoprotein receptor (LDLR) cardiovascular disease (CVD) hypercholesterolemia alirocmab evolocumab
DOI	10.2174/1389557518666180423111442
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4560706
专题	山东大学
作者单位	Shandong Univ, Sch Pharmaceut Sci, Key Lab Chem Biol, Inst Med Chem,Minist Educ, Jinan 250012, Shandong, Peoples R China.
推荐引用方式 GB/T 7714	Wang, Yan,Liu, Zhao-Peng. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY,2019,19(2):165-176.
APA	Wang, Yan,&Liu, Zhao-Peng.(2019).PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol.MINI-REVIEWS IN MEDICINAL CHEMISTRY,19(2),165-176.
MLA	Wang, Yan,et al."PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol".MINI-REVIEWS IN MEDICINAL CHEMISTRY 19.2(2019):165-176.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。